| Literature DB >> 31647549 |
Scott P Allen1, Benjamin Hall1, Ryan Woof1, Laura Francis2, Noemi Gatto1, Allan C Shaw1, Monika Myszczynska1, Jordan Hemingway1, Ian Coldicott1, Amelia Willcock1, Lucy Job1, Rachel M Hughes1, Camilla Boschian1, Nadhim Bayatti1, Paul R Heath1, Oliver Bandmann1, Heather Mortiboys1, Laura Ferraiuolo1, Pamela J Shaw1.
Abstract
It is important to understand how the disease process affects the metabolic pathways in amyotrophic lateral sclerosis and whether these pathways can be manipulated to ameliorate disease progression. To analyse the basis of the metabolic defect in amyotrophic lateral sclerosis we used a phenotypic metabolic profiling approach. Using fibroblasts and reprogrammed induced astrocytes from C9orf72 and sporadic amyotrophic lateral sclerosis cases we measured the production rate of reduced nicotinamide adenine dinucleotides (NADH) from 91 potential energy substrates simultaneously. Our screening approach identified that C9orf72 and sporadic amyotrophic lateral sclerosis induced astrocytes have distinct metabolic profiles compared to controls and displayed a loss of metabolic flexibility that was not observed in fibroblast models. This loss of metabolic flexibility, involving defects in adenosine, fructose and glycogen metabolism, as well as disruptions in the membrane transport of mitochondrial specific energy substrates, contributed to increased starvation induced toxicity in C9orf72 induced astrocytes. A reduction in glycogen metabolism was attributed to loss of glycogen phosphorylase and phosphoglucomutase at the protein level in both C9orf72 induced astrocytes and induced neurons. In addition, we found alterations in the levels of fructose metabolism enzymes and a reduction in the methylglyoxal removal enzyme GLO1 in both C9orf72 and sporadic models of disease. Our data show that metabolic flexibility is important in the CNS in times of bioenergetic stress.Entities:
Keywords: zzm321990 C9orf72zzm321990 ; ALS; astrocytes; metabolism; methylglyoxal
Mesh:
Substances:
Year: 2019 PMID: 31647549 PMCID: PMC6906594 DOI: 10.1093/brain/awz302
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501